CANDANCE GUINN: Open Payments
NPI 1114578168 · EL DORADO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$648 in 31 payments from 6 companies in 2025. Trend: 2023 $278 · 2024 $472 · 2025 $648
Food & beverage: $648
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $261 |
| ABBVIE INC. | 12 | $245 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
Products named: CAPLYTA, VRAYLAR, REXULTI, Auvelity, INGREZZA, Qelbree.
Industry payments across AR — which companies pay providers there.
